Trials / Completed
CompletedNCT01404104
Neo-adjuvant Temsirolimus in Patients With Advanced Renal Cell Carcinoma
A Pilot Study of Neo-adjuvant Temsirolimus in Patients With Advanced Renal Cell Carcinoma Undergoing Definitive Therapy With Radical Nephrectomy, or Cytoreductive Nephrectomy: Analysis if Serum and Tissue Biomarkers
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- St. Joseph's Healthcare Hamilton · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Temsirolimus is a drug that is being studied to possibly treat kidney cancer. It works by starving the cancer of nutrients, by cutting off the blood supply, which is hoping to shrink the cancer. This study will look at the experimental use of temsirolimus, 12 weeks prior to the surgical removal of the entire kidney or a portion of the kidney that is involved by the tumor.
Detailed description
This study will also find out whether or not there are certain biological factors that show up in patients during their treatment with this drug. This will be able to predict how their disease will respond to the therapy (biomarkers), and this will possibly allow anti-cancer therapies to be developed in the future to tailor to a patient's needs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Temsirolimus (pre surgery) | Temsirolimus will be given to patients 12 weeks prior to surgery (with a one week off period right before the surgery date). |
Timeline
- Start date
- 2008-09-01
- Primary completion
- 2014-08-01
- Completion
- 2014-08-01
- First posted
- 2011-07-27
- Last updated
- 2016-07-27
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT01404104. Inclusion in this directory is not an endorsement.